Companies › China Immunotech (Beijing) Biotechnology
1 active drug program in 6 registered trials: 6 Phase 1; Hematology, Immunology; next expected readout Nov 2026.
Open in Phaseline: competitors, likelihood bands and readouts Company report
| Drug | Target | Highest phase | Conditions | Next expected readout |
|---|---|---|---|---|
| YTS109 cells STAR-T cell therapy | – | Phase 1 | Lupus Nephritis (LN); Systemic Lupus Erythematosus (SLE); Systemic Lupus Erythematosus | Nov 2026 |
| Registry id | Drug | Phase | Conditions | Area | Expected readout |
|---|---|---|---|---|---|
| NCT06943937 | YTS109 cells | Phase 1 | Lupus Nephritis (LN) | Hematology | Apr 2026 |
| NCT07236801 | YTS109 cells | Phase 1 | Systemic Lupus Erythematosus (SLE) | Immunology | Nov 2026 |
| NCT07236762 | YTS109 cells | Phase 1 | Systemic Lupus Erythematosus | Immunology | Nov 2026 |
| NCT06978647 | YTS109 cells | Phase 1 | Systemic Lupus Erythematosus (SLE) | Immunology | May 2027 |
| NCT07123519 | YTS109 cells | Phase 1 | Systemic Lupus Erythematosus (SLE) | Immunology | Aug 2027 |
| NCT07104721 | YTS109 cells | Phase 1 | Systemic Lupus Erythematosus (SLE) | Immunology | Dec 2028 |
No annotated target.
–
Programs group the company's trials by drug; the target and mechanism come from Open Targets and ChEMBL via Open Targets; expected readouts are Phaseline's estimate from the registry's primary completion date. Facts from the registries only; the approval likelihood, shown as a band with its track record, is in the app.